Atlas Trials

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Clinical trial NCT07187869 · RECRUITING

Trial details

NCT number
NCT07187869
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Clear Cell Renal Cell Carcinoma
Start date
2026-02-12
Primary completion
2027-04-07
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.